Wetenschappelijke publicaties van Bordet

Wetenschappelijke publicaties van Bordet

Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7 <sup>th</sup> immunorad conference.

Laurent PA, André F, Bobard A, Deandreis D, Demaria S, Depil S, Eichmüller SB, Fernandez-Palomo C, Foijer F, Galluzzi L, Galon J, Guckenberger M, Harrington KJ, Herrera FG, Huber PE, Italiano A, Karam SD, Kroemer G, Lambin P, Leuschner C, Mantovani A, Meylan E, Mondini M, Pittet MJ, Pouget JP, Remon J, Sørensen CS, Sotiriou C, Vanpouille-Box C, Weichselbaum RR, Welsh JW, Zitvogel L, Formenti SC, Deutsch E

Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7 <sup>th</sup> immunorad conference.

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC).

Fernandez-Martinez A, Tanioka M, Ahn SG, Zagami P, Pascual T, Rediti M, Tang G, Hoadley KA, Venet D, Rashid NU, Spears PA, Di Cosimo S, de Azambuja E, Choudhury A, Rastogi P, Islam MN, Cortes J, Llombart-Cussac A, Swain SM, Sotiriou C, Prat A, Perou CM, Carey LA

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC).

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC).

Fernandez-Martinez A, Tanioka M, Ahn SG, Zagami P, Pascual T, Rediti M, Tang G, Hoadley KA, Venet D, Rashid NU, Spears PA, Di Cosimo S, de Azambuja E, Choudhury A, Rastogi P, Islam MN, Cortes J, Llombart-Cussac A, Swain SM, Sotiriou C, Prat A, Perou CM, Carey LA

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC).

Drug-drug interactions between palbociclib and proton pump inhibitors in&nbsp;early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Agostinetto E, Pfeiler G, Hlauschek D, Mayer EL, Lambertini M, de Azambuja E, Bellet-Ezquerra M, Meisel JL, Rubovszky G, Zdenkowski N, Novik Y, Ruiz-Borrego M, Gelmon KA, Mamounas EP, Iwata H, Lu DR, Soelkner L, Fesl C, Gnant M, DeMichele A

Drug-drug interactions between palbociclib and proton pump inhibitors in&nbsp;early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Drug-drug interactions between palbociclib and proton pump inhibitors in&nbsp;early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Agostinetto E, Pfeiler G, Hlauschek D, Mayer EL, Lambertini M, de Azambuja E, Bellet-Ezquerra M, Meisel JL, Rubovszky G, Zdenkowski N, Novik Y, Ruiz-Borrego M, Gelmon KA, Mamounas EP, Iwata H, Lu DR, Soelkner L, Fesl C, Gnant M, DeMichele A

Drug-drug interactions between palbociclib and proton pump inhibitors in&nbsp;early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
Erasme hospital

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Wetenschappelijke publicaties van Erasmus
Huderf hospital

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Wetenschappelijke publicaties van het Koningin Fabiola-Kinderziekenhuis
Bordet hospital

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Jules Bordet